LL-37 5 mg | Human Cathelicidin Antimicrobial Peptide

LL-37 (also known as hCAP18 or CAMP) is the sole human cathelicidin — a 37-amino-acid, amphipathic, alpha-helical peptide that serves as a key effector of the innate immune system. It is produced by neutrophils, monocytes/macrophages, and barrier epithelial cells (skin, gut, respiratory tract) in response to infection and tissue damage.

Research Background

Broad-spectrum antimicrobial activity — LL-37 has been studied for direct antimicrobial effects against gram-positive bacteria, gram-negative bacteria, fungi, and enveloped viruses. Its amphipathic structure disrupts microbial membranes through electrostatic interaction with negatively charged lipid bilayers.

Biofilm disruption — A particularly active area of LL-37 research involves its ability to prevent biofilm formation and disrupt established biofilms — a critical challenge in chronic infection research where biofilm-dwelling bacteria are resistant to conventional antimicrobials.

Immunomodulation — Beyond direct antimicrobial activity, LL-37 modulates immune cell chemotaxis, cytokine expression, and wound healing. It recruits immune cells to sites of infection and influences the transition from innate to adaptive immune responses.

Wound healing — Research suggests LL-37 promotes re-epithelialisation and angiogenesis in wound models, linking its antimicrobial and tissue-repair roles.

Related Products

See also Thymosin Alpha-1, KPV (anti-inflammatory tripeptide), and LZ1. Browse Immune Support.

For research use only. Not for human or veterinary consumption.